Sarah Cannon Research Institute
‘Burnout is actionable’: 6 organizational strategies to promote wellness among oncologists
Ishwaria M. Subbiah, MD, MS, FASCO, is a third-generation health care professional and second-generation medical oncologist.
FDA gives accelerated approval to Epkinly for advanced follicular lymphoma
The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more previous lines of therapy.
Durvalumab extends survival in limited-stage small-cell lung cancer
CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.
Regimen confers ‘clinically meaningful’ PFS benefit in relapsed multiple myeloma
CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with standard care for patients with relapsed or refractory multiple myeloma, according to data presented at ASCO Annual Meeting.
Gene therapy a potential ‘functional cure’ for sickle cell disease, beta thalassemia
Treatment with exagamglogene autotemcel conferred clinically meaningful increases in fetal hemoglobin and total hemoglobin levels among patients with beta-thalassemia and sickle cell disease, results of two pivotal studies showed.
5 women at forefront of oncology digital space
Today marks International Women’s Day.
Anti-TIGIT regimens improve outcomes vs. anti-PD-1 alone in lung cancer subgroup
A novel anti-TIGIT antibody improved overall response rates and extended PFS when added to anti-PD-1 therapy and to anti-PD-1 therapy plus an adenosine receptor antagonist for patients with advanced, PD-L1-high non-small cell lung cancer.
Trastuzumab deruxtecan safe for HER2-positive metastatic breast cancer, analysis shows
CHICAGO — Trastuzumab deruxtecan exhibited a tolerable safety profile with longer follow-up among patients with HER2-positive unresectable and/or metastatic breast cancer in the DESTINY-Breast03 trial, a study at ASCO Annual Meeting showed.
First-line durvalumab-tremelimumab regimen improves outcomes in NSCLC subset
First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results.
Sarah Cannon appoints deputy physician-in-chief of blood cancers
Navneet Majhail, MD, MS, FASTCT, has been appointed deputy physician-in-chief of blood cancers for Sarah Cannon Transplant and Cellular Therapy Network.